In patients with severe left ventricular systolic dysfunction on optimal medical therapy for HF, undergoing PCI did not improve rates of all-cause death or HF hospitalization, according to the results ...

Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

The US Food and Drug Administration (FDA) has approved sacubitril/valsartan (Entresto, Novartis) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

BELGRADE, Serbia—An artificial intelligence algorithm for interpreting electrocardiograms (AI-ECG) can identify individuals who have subclinical heart failure (HF) when echocardiography isn’t widely ...

Systolic congestive heart failure, or systolic heart failure, is a type of heart failure that involves the left side of the heart. As the left side of the heart begins losing some function, it loses ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.